Faithward's Strategic Investments
Faithward Advisors Expands Multi-Million Dollar Portfolio Across Healthcare, Finance, and Large-Cap ETFs
Anonymous
Key Points
1
For Xeris Biopharma (XERS), Vanguard Group reported owning 11,186,677 shares worth $87,815,000 after adding 1,358,760 shares, and the filing context notes hedge funds/institutions hold 42.75% of the stock.
2
In United Therapeutics (UTHR), the coverage emphasizes that institutional investors own 94.08% of the company, and it cites major new/added positions including Norges Bank’s $293,418,000 stake and Baillie Gifford & Co.’s $157,390,000 stake.
3
For W.R. Berkley (WRB), the article highlights analyst actions: Bank of America cut its price objective from $68 to $67 and kept a “neutral” rating, while Goldman Sachs upgraded WRB from “neutral” to “buy” and raised its target from $71 to $73.
4
For United States Antimony (UAMY), Weiss Ratings’ coverage is specifically noted: it assumed coverage and issued a “sell (d-)” rating. The piece also reports institutional/hedge-fund ownership at 9.49%.
5
Regarding the Putnam Focused Large Cap Value ETF (PVAL), the coverage adds that it is an actively-managed, non-transparent ETF using the Fidelity non-transparent model, launched May 25, 2021 and managed by Putnam.
Faithward Advisors LLC put $838,000 into Xeris Biopharma in the fourth quarter, part of a sweeping portfolio expansion that also included a new $3.5 million stake in United Therapeutics and a $3.1 million buy into the Putnam Focused Large Cap Value ETF, according to Watchlist News.
The Lancaster, Pennsylvania-based firm — which manages over $1.1 billion using a faith-based investment philosophy — also boosted its W.R. Berkley stake by 185% and initiated a brand-new position in domestic minerals supplier United States Antimony. Across all five moves, Faithward is making a clear bet on healthcare, insurance, and large-cap value.
Xeris Biopharma Bet Comes as Company Cuts Debt
Faithward's $838,000 Xeris buy lands at a pivotal moment for the biopharma company. On June 11, Xeris announced a private exchange of $23 million in convertible notes due 2028, cutting its annual interest costs by $2 million, according to Business Wire. That move signals a shift from a debt-heavy R&D model to a leaner commercial operation.
Institutional confidence in Xeris is growing fast. Vanguard Group now holds 11,186,677 shares worth $87.8 million after adding 1,358,760 shares, per Stock Titan. Granahan Investment Management lifted its stake by 249%, according to MarketBeat. Total institutional ownership sits at roughly 62.7%, per Simply Wall St.
United Therapeutics Buy Joins a Crowded Institutional Trade
Faithward's $3.5 million United Therapeutics position puts it alongside some of the world's biggest investors. Institutions own 94.08% of the company, according to Watchlist News. Norway's Norges Bank holds a $293.4 million stake. Baillie Gifford & Co. holds $157.4 million. Faithward is a small player in a very large room.
W.R. Berkley drew a 185% stake increase from Faithward, bringing its holdings to 33,095 shares worth roughly $2.3 million. Analysts are split on the insurance stock. Bank of America cut its price target from $68 to $67 and kept a "neutral" rating. Goldman Sachs went the other way, upgrading the stock to "buy" and raising its target to $73, per Watchlist News.
Antimony Bet Pits Faithward Against a Sell Rating
Faithward's most contrarian move was buying 234,678 shares of United States Antimony for $1.18 million. Weiss Ratings issued a "Sell (d-)" rating on the stock. But bulls point to a dramatic price surge: antimony has jumped from $5.96 to $28.72 per pound, making the company a rare domestic alternative to Chinese supply, according to MarketBeat.
H.C. Wainwright analyst Heiko F. Ihle reiterated a "Strong Buy" on the stock with an $11.75 price target as recently as May 18. Institutional and hedge fund ownership sits at just 9.49%, per Watchlist News, meaning there is a lot of room for a re-rating if UAMY hits its $125 million revenue target for 2026.
A $3.1 Million ETF Bet on Active, Hidden Holdings
Faithward also put $3.1 million into the Putnam Focused Large Cap Value ETF (PVAL). The fund is actively managed and non-transparent — meaning it does not disclose its holdings every day. That structure, based on the Fidelity non-transparent model, lets managers trade without getting "front-run" by high-frequency traders, according to Charles Schwab.
PVAL launched on May 25, 2021, and is run by Putnam Investments, now part of Franklin Templeton. Senior Portfolio Manager Caroline Edwards oversees the fund. Faithward's buy suggests the firm sees more value in active stock-picking — done behind closed doors — than in plain index funds in today's volatile market.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
13
Articles
4
Reach
17
A
AnonymousAuthor
